Please assess the completion status of the following clinical trial:

Trial Title: Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Males aged 18 or over~* Histologically proven adenocarcinoma of the prostate (all stages) in whom endocrine treatment was indicated (except neoadjuvant hormonal therapy)~* Has completed Study FE200486 CS07~* Has not met a withdrawal criteria at Visit 9 (day 28) in Study FE200486 CS07

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Degarelix 120 mg (20 mg/mL) (Type: EXPERIMENTAL): Degarelix 120 mg (20 mg/mL)
- Degarelix 120 mg (40 mg/mL) (Type: EXPERIMENTAL): Degarelix 120 mg (40 mg/mL)
- Degarelix 160 mg (40 mg/mL) (Type: EXPERIMENTAL): Degarelix 160 mg (40 mg/mL)
- Degarelix 200 mg (40 mg/mL) (Type: EXPERIMENTAL): Degarelix 200 mg (40 mg/mL)
- Degarelix 200 mg (60 mg/mL) (Type: EXPERIMENTAL): Degarelix 200 mg (60 mg/mL)
- Degarelix 240 mg (40 mg/mL) (Type: EXPERIMENTAL): Degarelix 240 mg (40 mg/mL)
- Degarelix 240 mg (60 mg/mL) (Type: EXPERIMENTAL): Degarelix 240 mg (60 mg/mL)
- Degarelix 320 mg (60 mg/mL) (Type: EXPERIMENTAL): Degarelix 320 mg (60 mg/mL)

Based on this trial design, predict the completion outcome and termination type (if applicable).